EFFECTIVE ROFERONE A THERAPY FOR THE TUMOR STAGE OF MYCOSIS FUNGOIDES: A CLINICAL CASE

E. A Ilyushkina; S. K Kravchenko; E. E Zvonkov; E. M Lezvinskaya; L. B Vazhbin

doi:10.17816/dv36728

Russian Journal of Skin and Venereal Diseases ›› 2012, Vol. 15 ›› Issue (6) : 7 -10. DOI: 10.17816/dv36728

Articles

research-article

EFFECTIVE ROFERONE A THERAPY FOR THE TUMOR STAGE OF MYCOSIS FUNGOIDES: A CLINICAL CASE

Author information +

History +

PDF

Abstract

A 34-year old female patient with the tumor stage of mycosis fungoides was treated (monotherapy) with roferone A (Switzerland). The treatment was carried out during 1 year. Complete remission lasting for more than 32 months was attained. This significant clinical effect as a result of interferon monotherapy without chemotherapeutic drugs and corticosteroids was attained for the first time in Russia.

Keywords

mycosis fungoides / therapy / roferone A

Cite this article

Download citation ▾

E. A Ilyushkina, S. K Kravchenko, E. E Zvonkov, E. M Lezvinskaya, L. B Vazhbin. EFFECTIVE ROFERONE A THERAPY FOR THE TUMOR STAGE OF MYCOSIS FUNGOIDES: A CLINICAL CASE. Russian Journal of Skin and Venereal Diseases, 2012, 15(6): 7-10 DOI:10.17816/dv36728

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Ершов Ф.И., Киселев О.И. Интерфероны и их индукторы. М.: ГЭОТАР-Медиа; 2005.

[2]	Лезвинская Е.М., Григорян С.С. Интерфероны в комплексной терапии больных злокачественными лимфомами кожи. В сб.: Материалы конференции, посвященной памяти А.Л. Машкиллейсона. М.: 2004: 6—7.

[3]

Agar N.S., Wedgeworth E., Crichton S., Mitchell T.J., Cox M., Ferreira S., et al. Survival outcomes and prognostic factors in mycosis fungoides/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J. Clin. Oncol. 2010; 28(31): 4730—9.

[4]	Kim Y.H., Liu H.L., Mraz-Gernhard S., Varghese A., Hoppe R.T. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch. Dermatol. 2003; 139(7): 857—66.

[5]	Dreno B., Godefroy W.Y., Fleischmann M., Bureau B., Litoux P. Lowdose recombinant interferon-alpha in the treatment of cutaneous T-cell lymphomas. Br. J. Dermatol. 1989; 121(4): 543—4.

[6]	Olsen E.A., Rosen S.T., Vollmer R.T., Variakojis D., Roenigk H.H. Jr., Diab N., Zeffren J. Interferon alfa-2a in the treatment of cutaneous T cell lymphoma. 1989; 20(3): 395—407.

[7]	Qiu B., Chen M. Treatment of cutaneous T-cell lymphoma with low doses of interferon alpha-2b. Chin. Med. J. (Engl). 1996; 109(5): 404—6.

[8]	Olsen E.A., Bunn P.A. Interferon in treatment of cutaneous T-cell lymphoma. Hematol. Oncol. Clin. N. Am. 1995; 9(5): 1089—107.

[9]	Papa G., Tura S., Mandelli F., Vegna M.L., Defazio D., Mazza P., et al. Is interferon alpha in cutaneous T-cell lymphoma a treatment of choice? Br. J. Haematol. 1991; 79(Suppl. 1): 48—51.